论文部分内容阅读
目的探讨雷替曲塞联合多西他赛二线治疗晚期胃癌的疗效及安全性。方法一线化疗治疗失败或缓解后再进展的35例晚期胃癌患者,给予雷替曲塞联合多西他赛方案化疗,21 d为1个周期,2个周期后评价疗效,观察化疗期间毒副反应。结果 35例患者中,0例完全缓解(CR),7例部分缓解(PR),15例稳定(SD),13例进展(PD),有效率(RR)为20.0%,疾病控制率(DCR)为62.9%,中位无进展生存时间(PFS)4.2个月。主要的毒副反应为血液毒性、关节疼痛、乏力、恶心呕吐、液体潴留、周围神经毒性及转氨酶升高,多为Ⅰ~Ⅱ度,对症处理后可逆转。结论雷替曲塞联合多西他赛二线治疗晚期胃癌,患者可获益,且不良反应可耐受,值得临床进一步证实。
Objective To investigate the efficacy and safety of ralterexed and docetaxel in the treatment of advanced gastric cancer. Methods 35 cases of advanced gastric cancer who failed to progress or remission after remission were given raltitrexed combined with docetaxel chemotherapy. The course of treatment was 1 cycle after 21 days. The curative effect was evaluated after 2 cycles. Toxic and side effects were observed during chemotherapy . Results Among the 35 patients, complete remission (CR), partial remission (PR), partial remission (15 cases), progressive progress (PD) and complete remission ) Was 62.9%, with a median progression-free survival time (PFS) of 4.2 months. The main side effects of hematotoxicity, joint pain, fatigue, nausea and vomiting, fluid retention, peripheral neurotoxicity and elevated transaminases, mostly Ⅰ ~ Ⅱ degree, symptomatic treatment can be reversed. Conclusions Raltitrexed combined with Docetaxel second-line therapy for advanced gastric cancer can benefit patients with adverse reactions and is worth further clinical confirmation.